25 XP   0   0   10

Alembic Pharmaceuticals Limited
Buy, Hold or Sell?

Let's analyse Alembic Pharmaceuticals Limited together

PenkeI guess you are interested in Alembic Pharmaceuticals Limited. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Alembic Pharmaceuticals Limited. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Alembic Pharmaceuticals Limited

I send you an email if I find something interesting about Alembic Pharmaceuticals Limited.

Quick analysis of Alembic Pharmaceuticals Limited (30 sec.)










What can you expect buying and holding a share of Alembic Pharmaceuticals Limited? (30 sec.)

How much money do you get?

How much money do you get?
INR0.48
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
INR222.34
Expected worth in 1 year
INR45.90
How sure are you?
90.0%

+ What do you gain per year?

Total Gains per Share
INR-136.45
Return On Investment
-14.7%

For what price can you sell your share?

Current Price per Share
INR931.05
Expected price per share
INR839.00 - INR1,094
How sure are you?
50%

1. Valuation of Alembic Pharmaceuticals Limited (5 min.)




Live pricePrice per Share (EOD)

INR931.05

Intrinsic Value Per Share

INR56.99 - INR605.81

Total Value Per Share

INR279.33 - INR828.15

2. Growth of Alembic Pharmaceuticals Limited (5 min.)




Is Alembic Pharmaceuticals Limited growing?

Current yearPrevious yearGrowGrow %
How rich?$524.4m$628.5m-$104m-19.8%

How much money is Alembic Pharmaceuticals Limited making?

Current yearPrevious yearGrowGrow %
Making money$41m$62.5m-$21.4m-52.3%
Net Profit Margin6.1%10.0%--

How much money comes from the company's main activities?

3. Financial Health of Alembic Pharmaceuticals Limited (5 min.)




What can you expect buying and holding a share of Alembic Pharmaceuticals Limited? (5 min.)

Welcome investor! Alembic Pharmaceuticals Limited's management wants to use your money to grow the business. In return you get a share of Alembic Pharmaceuticals Limited.

What can you expect buying and holding a share of Alembic Pharmaceuticals Limited?

First you should know what it really means to hold a share of Alembic Pharmaceuticals Limited. And how you can make/lose money.

Speculation

The Price per Share of Alembic Pharmaceuticals Limited is INR931.05. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Alembic Pharmaceuticals Limited.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Alembic Pharmaceuticals Limited, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is INR222.34. Based on the TTM, the Book Value Change Per Share is INR-44.11 per quarter. Based on the YOY, the Book Value Change Per Share is INR8.68 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is INR10.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Alembic Pharmaceuticals Limited.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 INR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per Share
Usd Eps0.210.0%0.210.0%0.320.0%0.420.0%0.340.0%
Usd Book Value Change Per Share-0.53-0.1%-0.53-0.1%0.100.0%0.260.0%0.240.0%
Usd Dividend Per Share0.120.0%0.120.0%0.170.0%0.140.0%0.090.0%
Usd Total Gains Per Share-0.410.0%-0.410.0%0.270.0%0.400.0%0.330.0%
Usd Price Per Share5.96-5.96-8.90-7.86-6.95-
Price to Earnings Ratio28.53-28.53-27.98-20.67-23.18-
Price-to-Total Gains Ratio-14.55--14.55-32.70-11.62-18.82-
Price to Book Ratio2.23-2.23-2.78-3.19-5.30-
Price-to-Total Gains Ratio-14.55--14.55-32.70-11.62-18.82-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share11.1726
Number of shares89
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.120.14
Usd Book Value Change Per Share-0.530.26
Usd Total Gains Per Share-0.410.40
Gains per Quarter (89 shares)-36.4336.01
Gains per Year (89 shares)-145.73144.04
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
143-188-1565193134
285-377-302101187278
3128-565-448152280422
4171-754-594202374566
5214-942-740253467710
6256-1131-886304561854
7299-1319-1032354654998
8342-1508-11784057481142
9384-1696-13244558411286
10427-1884-14705069351430

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%13.00.00.0100.0%
Book Value Change Per Share0.01.00.00.0%2.01.00.066.7%4.01.00.080.0%9.01.00.090.0%12.01.00.092.3%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%12.00.01.092.3%
Total Gains per Share0.01.00.00.0%2.01.00.066.7%4.01.00.080.0%9.01.00.090.0%12.01.00.092.3%

Fundamentals of Alembic Pharmaceuticals Limited

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company provides branded specialty medicines in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, veterinary, and anti-diabetic; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.

Fundamental data was last updated by Penke on 2024-04-09 10:49:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is fair priced.

1.1. Profitability of Alembic Pharmaceuticals Limited.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Alembic Pharmaceuticals Limited earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compare Alembic Pharmaceuticals Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 6.1% means that ₹0.06 for each ₹1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Alembic Pharmaceuticals Limited:

  • The MRQ is 6.1%. The company is making a profit. +1
  • The TTM is 6.1%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ6.1%TTM6.1%0.0%
TTM6.1%YOY10.0%-3.9%
TTM6.1%5Y14.3%-8.3%
5Y14.3%10Y14.8%-0.5%
1.1.2. Return on Assets

Shows how efficient Alembic Pharmaceuticals Limited is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Alembic Pharmaceuticals Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • 5.5% Return on Assets means that Alembic Pharmaceuticals Limited generated ₹0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Alembic Pharmaceuticals Limited:

  • The MRQ is 5.5%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 5.5%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ5.5%TTM5.5%0.0%
TTM5.5%YOY7.3%-1.8%
TTM5.5%5Y11.2%-5.7%
5Y11.2%10Y14.7%-3.5%
1.1.3. Return on Equity

Shows how efficient Alembic Pharmaceuticals Limited is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Alembic Pharmaceuticals Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • 7.8% Return on Equity means Alembic Pharmaceuticals Limited generated ₹0.08 for each ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Alembic Pharmaceuticals Limited:

  • The MRQ is 7.8%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 7.8%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ7.8%TTM7.8%0.0%
TTM7.8%YOY9.9%-2.1%
TTM7.8%5Y17.5%-9.6%
5Y17.5%10Y23.9%-6.4%

1.2. Operating Efficiency of Alembic Pharmaceuticals Limited.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Alembic Pharmaceuticals Limited is operating .

  • Measures how much profit Alembic Pharmaceuticals Limited makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Alembic Pharmaceuticals Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 7.2% means the company generated ₹0.07  for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Alembic Pharmaceuticals Limited:

  • The MRQ is 7.2%. The company is operating less efficient.
  • The TTM is 7.2%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ7.2%TTM7.2%0.0%
TTM7.2%YOY12.2%-5.0%
TTM7.2%5Y17.9%-10.8%
5Y17.9%10Y19.0%-1.1%
1.2.2. Operating Ratio

Measures how efficient Alembic Pharmaceuticals Limited is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.92 means that the operating costs are ₹0.92 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of Alembic Pharmaceuticals Limited:

  • The MRQ is 0.923. The company is less efficient in keeping operating costs low.
  • The TTM is 0.923. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.923TTM0.9230.000
TTM0.923YOY0.887+0.037
TTM0.9235Y0.824+0.100
5Y0.82410Y0.812+0.011

1.3. Liquidity of Alembic Pharmaceuticals Limited.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Alembic Pharmaceuticals Limited is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.78 means the company has ₹1.78 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of Alembic Pharmaceuticals Limited:

  • The MRQ is 1.778. The company is able to pay all its short-term debts. +1
  • The TTM is 1.778. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.778TTM1.7780.000
TTM1.778YOY1.667+0.111
TTM1.7785Y1.635+0.142
5Y1.63510Y1.670-0.034
1.3.2. Quick Ratio

Measures if Alembic Pharmaceuticals Limited is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Alembic Pharmaceuticals Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.76 means the company can pay off ₹0.76 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Alembic Pharmaceuticals Limited:

  • The MRQ is 0.756. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.756. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.756TTM0.7560.000
TTM0.756YOY0.747+0.009
TTM0.7565Y0.778-0.022
5Y0.77810Y0.746+0.032

1.4. Solvency of Alembic Pharmaceuticals Limited.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Alembic Pharmaceuticals Limited assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Alembic Pharmaceuticals Limited to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.29 means that Alembic Pharmaceuticals Limited assets are financed with 29.3% credit (debt) and the remaining percentage (100% - 29.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Alembic Pharmaceuticals Limited:

  • The MRQ is 0.293. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.293. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.293TTM0.2930.000
TTM0.293YOY0.265+0.029
TTM0.2935Y0.340-0.047
5Y0.34010Y0.369-0.028
1.4.2. Debt to Equity Ratio

Measures if Alembic Pharmaceuticals Limited is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Alembic Pharmaceuticals Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 41.5% means that company has ₹0.41 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Alembic Pharmaceuticals Limited:

  • The MRQ is 0.415. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.415. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.415TTM0.4150.000
TTM0.415YOY0.360+0.055
TTM0.4155Y0.544-0.130
5Y0.54410Y0.610-0.066

2. Market Valuation of Alembic Pharmaceuticals Limited

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₹1 in earnings Alembic Pharmaceuticals Limited generates.

  • Above 15 is considered overpriced but always compare Alembic Pharmaceuticals Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 28.53 means the investor is paying ₹28.53 for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Alembic Pharmaceuticals Limited:

  • The EOD is 53.513. Based on the earnings, the company is expensive. -2
  • The MRQ is 28.528. Based on the earnings, the company is overpriced. -1
  • The TTM is 28.528. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD53.513MRQ28.528+24.985
MRQ28.528TTM28.5280.000
TTM28.528YOY27.982+0.546
TTM28.5285Y20.674+7.854
5Y20.67410Y23.179-2.505
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Alembic Pharmaceuticals Limited:

  • The EOD is 65.235. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The MRQ is 34.777. Based on how much money comes from the company's main activities, the company is fair priced.
  • The TTM is 34.777. Based on how much money comes from the company's main activities, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD65.235MRQ34.777+30.458
MRQ34.777TTM34.7770.000
TTM34.777YOY115.043-80.266
TTM34.7775Y71.760-36.982
5Y71.76010Y15.237+56.522
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Alembic Pharmaceuticals Limited is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 2.23 means the investor is paying ₹2.23 for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of Alembic Pharmaceuticals Limited:

  • The EOD is 4.187. Based on the equity, the company is fair priced.
  • The MRQ is 2.232. Based on the equity, the company is underpriced. +1
  • The TTM is 2.232. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD4.187MRQ2.232+1.955
MRQ2.232TTM2.2320.000
TTM2.232YOY2.783-0.551
TTM2.2325Y3.188-0.956
5Y3.18810Y5.302-2.115
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Alembic Pharmaceuticals Limited compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---44.112-44.1120%8.678-608%21.876-302%19.676-324%
Book Value Per Share--222.344222.3440%266.456-17%209.434+6%141.766+57%
Current Ratio--1.7781.7780%1.667+7%1.635+9%1.670+6%
Debt To Asset Ratio--0.2930.2930%0.265+11%0.340-14%0.369-20%
Debt To Equity Ratio--0.4150.4150%0.360+15%0.544-24%0.610-32%
Dividend Per Share--10.00010.0000%14.000-29%11.842-16%7.784+28%
Eps--17.39817.3980%26.502-34%35.146-50%28.024-38%
Free Cash Flow Per Share--14.27214.2720%6.446+121%9.900+44%5.145+177%
Free Cash Flow To Equity Per Share--0.9450.9450%-4.611+588%1.120-16%1.332-29%
Gross Profit Margin---1.785-1.7850%-0.709-60%-0.350-80%-0.072-96%
Intrinsic Value_10Y_max--605.808--------
Intrinsic Value_10Y_min--56.988--------
Intrinsic Value_1Y_max--29.264--------
Intrinsic Value_1Y_min--5.342--------
Intrinsic Value_3Y_max--111.889--------
Intrinsic Value_3Y_min--16.464--------
Intrinsic Value_5Y_max--223.404--------
Intrinsic Value_5Y_min--27.956--------
Market Cap183009988598.400+47%97564106597.40097564106597.4000%145771212758.400-33%128746833330.360-24%113786408431.260-14%
Net Profit Margin--0.0610.0610%0.100-39%0.143-58%0.148-59%
Operating Margin--0.0720.0720%0.122-41%0.179-60%0.190-62%
Operating Ratio--0.9230.9230%0.887+4%0.824+12%0.812+14%
Pb Ratio4.187+47%2.2322.2320%2.783-20%3.188-30%5.302-58%
Pe Ratio53.513+47%28.52828.5280%27.982+2%20.674+38%23.179+23%
Price Per Share931.050+47%496.350496.3500%741.600-33%654.990-24%578.880-14%
Price To Free Cash Flow Ratio65.235+47%34.77734.7770%115.043-70%71.760-52%15.237+128%
Price To Total Gains Ratio-27.294-88%-14.551-14.5510%32.701-144%11.616-225%18.820-177%
Quick Ratio--0.7560.7560%0.747+1%0.778-3%0.746+1%
Return On Assets--0.0550.0550%0.073-24%0.112-51%0.147-62%
Return On Equity--0.0780.0780%0.099-21%0.175-55%0.239-67%
Total Gains Per Share---34.112-34.1120%22.678-250%33.718-201%27.460-224%
Usd Book Value--524456400.000524456400.0000%628506000.000-17%494003280.000+6%334390410.000+57%
Usd Book Value Change Per Share---0.529-0.5290%0.104-608%0.263-302%0.236-324%
Usd Book Value Per Share--2.6682.6680%3.197-17%2.513+6%1.701+57%
Usd Dividend Per Share--0.1200.1200%0.168-29%0.142-16%0.093+28%
Usd Eps--0.2090.2090%0.318-34%0.422-50%0.336-38%
Usd Free Cash Flow--33664800.00033664800.0000%15205200.000+121%23350560.000+44%12134906.400+177%
Usd Free Cash Flow Per Share--0.1710.1710%0.077+121%0.119+44%0.062+177%
Usd Free Cash Flow To Equity Per Share--0.0110.0110%-0.055+588%0.013-16%0.016-29%
Usd Market Cap2196119863.181+47%1170769279.1691170769279.1690%1749254553.101-33%1544961999.964-24%1365436901.175-14%
Usd Price Per Share11.173+47%5.9565.9560%8.899-33%7.860-24%6.947-14%
Usd Profit--41038800.00041038800.0000%62512800.000-34%82142880.000-50%65715477.600-38%
Usd Revenue--678314400.000678314400.0000%627814800.000+8%587021040.000+16%450404529.600+51%
Usd Total Gains Per Share---0.409-0.4090%0.272-250%0.405-201%0.330-224%
 EOD+3 -5MRQTTM+0 -0YOY+11 -255Y+13 -2310Y+15 -21

3.2. Fundamental Score

Let's check the fundamental score of Alembic Pharmaceuticals Limited based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1553.513
Price to Book Ratio (EOD)Between0-14.187
Net Profit Margin (MRQ)Greater than00.061
Operating Margin (MRQ)Greater than00.072
Quick Ratio (MRQ)Greater than10.756
Current Ratio (MRQ)Greater than11.778
Debt to Asset Ratio (MRQ)Less than10.293
Debt to Equity Ratio (MRQ)Less than10.415
Return on Equity (MRQ)Greater than0.150.078
Return on Assets (MRQ)Greater than0.050.055
Total6/10 (60.0%)

3.3. Technical Score

Let's check the technical score of Alembic Pharmaceuticals Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose960.000
Total1/1 (100.0%)



Latest Balance Sheet

Balance Sheet of 2023-03-31. Currency in INR. All numbers in thousands.

Summary
Total Assets61,828,300
Total Liabilities18,123,600
Total Stockholder Equity43,704,700
 As reported
Total Liabilities 18,123,600
Total Stockholder Equity+ 43,704,700
Total Assets = 61,828,300

Assets

Total Assets61,828,300
Total Current Assets29,100,200
Long-term Assets32,728,100
Total Current Assets
Cash And Cash Equivalents 754,800
Short-term Investments 166,400
Net Receivables 11,291,100
Inventory 14,752,700
Other Current Assets 2,135,200
Total Current Assets  (as reported)29,100,200
Total Current Assets  (calculated)29,100,200
+/-0
Long-term Assets
Property Plant Equipment 29,997,300
Other Assets 1,230,100
Long-term Assets  (as reported)32,728,100
Long-term Assets  (calculated)31,227,400
+/- 1,500,700

Liabilities & Shareholders' Equity

Total Current Liabilities16,369,300
Long-term Liabilities1,754,300
Total Stockholder Equity43,704,700
Total Current Liabilities
Short-term Debt 6,527,900
Short Long Term Debt 6,358,700
Accounts payable 6,798,100
Other Current Liabilities 855,400
Total Current Liabilities  (as reported)16,369,300
Total Current Liabilities  (calculated)20,540,100
+/- 4,170,800
Long-term Liabilities
Long term Debt Total 692,300
Capital Lease Obligations 861,500
Long-term Liabilities Other 200
Long-term Liabilities  (as reported)1,754,300
Long-term Liabilities  (calculated)1,554,000
+/- 200,300
Total Stockholder Equity
Common Stock393,100
Retained Earnings 35,684,400
Accumulated Other Comprehensive Income 335,400
Capital Surplus 7,483,900
Total Stockholder Equity (as reported)43,704,700
Total Stockholder Equity (calculated)43,896,800
+/- 192,100
Other
Capital Stock393,100
Cash and Short Term Investments 921,200
Common Stock Shares Outstanding 196,563
Current Deferred Revenue2,187,900
Liabilities and Stockholders Equity 61,828,300
Net Debt 6,465,400
Net Invested Capital 50,063,400
Net Working Capital 12,730,900
Property Plant and Equipment Gross 29,997,300
Short Long Term Debt Total 7,220,200



Balance Sheet

Currency in INR. All numbers in thousands.

 Trend2023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-312016-03-312015-03-312014-03-312013-03-312012-03-312011-03-31
> Total Assets 
8,436,482
10,519,041
10,478,242
12,178,017
16,411,675
24,593,802
26,866,800
39,410,300
47,777,600
59,890,500
67,089,800
71,220,300
61,828,300
61,828,30071,220,30067,089,80059,890,50047,777,60039,410,30026,866,80024,593,80216,411,67512,178,01710,478,24210,519,0418,436,482
   > Total Current Assets 
5,418,908
6,875,513
6,321,593
7,551,746
8,907,391
15,065,632
13,210,600
18,247,500
19,577,300
24,627,500
25,779,000
28,607,900
29,100,200
29,100,20028,607,90025,779,00024,627,50019,577,30018,247,50013,210,60015,065,6328,907,3917,551,7466,321,5936,875,5135,418,908
       Cash And Cash Equivalents 
62,893
470,805
161,060
239,613
268,256
4,508,291
1,530,800
837,500
1,990,700
718,400
980,600
610,900
754,800
754,800610,900980,600718,4001,990,700837,5001,530,8004,508,291268,256239,613161,060470,80562,893
       Short-term Investments 
0
0
0
0
0
0
0
121,800
91,000
1,869,700
1,869,700
316,200
166,400
166,400316,2001,869,7001,869,70091,000121,8000000000
       Net Receivables 
0
0
0
2,733,729
3,611,673
3,504,800
3,388,200
5,297,900
6,152,600
12,033,600
8,067,300
11,900,100
11,291,100
11,291,10011,900,1008,067,30012,033,6006,152,6005,297,9003,388,2003,504,8003,611,6732,733,729000
       Inventory 
2,192,319
2,587,415
2,668,333
3,107,782
3,827,706
5,775,798
6,327,500
7,339,300
9,672,600
11,875,300
14,861,500
16,097,000
14,752,700
14,752,70016,097,00014,861,50011,875,3009,672,6007,339,3006,327,5005,775,7983,827,7063,107,7822,668,3332,587,4152,192,319
       Other Current Assets 
3,163,696
3,817,293
3,492,200
4,204,351
4,811,429
4,781,543
5,352,300
9,948,900
1,761,400
200
-100
-100
2,135,200
2,135,200-100-1002001,761,4009,948,9005,352,3004,781,5434,811,4294,204,3513,492,2003,817,2933,163,696
   > Long-term Assets 
3,017,574
3,643,528
4,156,649
4,626,271
7,504,284
9,528,170
13,656,200
21,162,800
28,202,000
35,263,000
41,310,800
42,612,400
32,728,100
32,728,10042,612,40041,310,80035,263,00028,202,00021,162,80013,656,2009,528,1707,504,2844,626,2714,156,6493,643,5283,017,574
       Property Plant Equipment 
2,984,957
3,260,616
3,764,833
4,176,298
5,947,316
8,237,453
11,686,800
18,377,600
24,399,900
30,990,100
36,480,300
39,472,600
29,997,300
29,997,30039,472,60036,480,30030,990,10024,399,90018,377,60011,686,8008,237,4535,947,3164,176,2983,764,8333,260,6162,984,957
       Goodwill 
0
0
0
0
352,807
435,585
0
37,700
36,000
0
0
0
0
000036,00037,7000435,585352,8070000
       Long Term Investments 
0
0
0
33,557
22,641
867,300
498,800
416,400
487,600
0
0
0
0
0000487,600416,400498,800867,30022,64133,557000
       Intangible Assets 
0
0
0
0
0
0
270,000
1,619,700
2,662,700
2,990,200
3,229,500
1,548,200
0
01,548,2003,229,5002,990,2002,662,7001,619,700270,000000000
       Long-term Assets Other 
32,617
382,912
391,816
449,973
1,204,161
855,132
1,699,400
833,200
1,103,400
-100
-100
348,800
537,400
537,400348,800-100-1001,103,400833,2001,699,400855,1321,204,161449,973391,816382,91232,617
> Total Liabilities 
5,483,644
6,569,057
5,448,815
5,422,322
7,565,291
8,588,406
7,854,600
17,206,000
20,597,300
27,986,000
16,420,100
18,844,800
18,123,600
18,123,60018,844,80016,420,10027,986,00020,597,30017,206,0007,854,6008,588,4067,565,2915,422,3225,448,8156,569,0575,483,644
   > Total Current Liabilities 
2,136,314
5,348,388
4,416,286
4,479,109
6,840,903
7,674,314
6,787,500
11,234,900
14,896,300
17,516,000
12,808,400
17,165,300
16,369,300
16,369,30017,165,30012,808,40017,516,00014,896,30011,234,9006,787,5007,674,3146,840,9034,479,1094,416,2865,348,3882,136,314
       Short-term Debt 
0
1,394,577
1,162,569
571,775
2,446,988
1,564,178
885,200
2,077,800
6,291,300
8,704,000
3,121,800
6,449,700
6,527,900
6,527,9006,449,7003,121,8008,704,0006,291,3002,077,800885,2001,564,1782,446,988571,7751,162,5691,394,5770
       Short Long Term Debt 
0
0
0
1,093,974
250,000
1,376,100
885,200
2,077,800
6,291,300
8,605,000
200
6,299,900
6,358,700
6,358,7006,299,9002008,605,0006,291,3002,077,800885,2001,376,100250,0001,093,974000
       Accounts payable 
0
2,091,453
5,565
8,831
9,632
8,798
11,500
2,000
50,900
6,259,300
6,687,700
7,063,900
6,798,100
6,798,1007,063,9006,687,7006,259,30050,9002,00011,5008,7989,6328,8315,5652,091,4530
       Other Current Liabilities 
2,136,314
1,862,358
3,248,152
3,898,503
4,384,283
6,101,338
5,792,900
9,155,100
8,518,000
418,900
200
-100
855,400
855,400-100200418,9008,518,0009,155,1005,792,9006,101,3384,384,2833,898,5033,248,1521,862,3582,136,314
   > Long-term Liabilities 
3,347,330
1,220,669
1,032,529
943,213
724,388
914,092
1,067,100
5,971,100
5,701,000
10,470,000
3,611,700
1,679,500
1,754,300
1,754,3001,679,5003,611,70010,470,0005,701,0005,971,1001,067,100914,092724,388943,2131,032,5291,220,6693,347,330
       Long term Debt Total 
0
0
0
0
0
0
0
5,000,000
4,993,000
8,869,900
2,714,300
721,400
692,300
692,300721,4002,714,3008,869,9004,993,0005,000,0000000000
       Other Liabilities 
0
0
0
421,013
536,386
840,100
941,500
762,100
708,000
867,100
897,400
958,100
0
0958,100897,400867,100708,000762,100941,500840,100536,386421,013000
> Total Stockholder Equity
2,952,838
3,949,984
5,029,427
6,755,696
8,846,384
16,005,396
19,011,100
22,201,400
27,188,200
32,194,100
51,276,100
52,375,500
43,704,700
43,704,70052,375,50051,276,10032,194,10027,188,20022,201,40019,011,10016,005,3968,846,3846,755,6965,029,4273,949,9842,952,838
   Common Stock
377,032
377,032
377,032
377,032
377,032
377,032
377,000
377,000
377,000
377,000
393,100
393,100
393,100
393,100393,100393,100377,000377,000377,000377,000377,032377,032377,032377,032377,032377,032
   Retained Earnings Total Equity0000000000000
   Accumulated Other Comprehensive Income 
-1,615,453
-1,950,891
-2,282,569
-2,681,209
-3,141,880
-3,878,237
-4,554,400
-2,455,400
-3,513,800
-4,951,500
18,513,800
18,808,800
335,400
335,40018,808,80018,513,800-4,951,500-3,513,800-2,455,400-4,554,400-3,878,237-3,141,880-2,681,209-2,282,569-1,950,891-1,615,453
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
7,483,900
7,483,900
7,483,900
7,483,9007,483,9007,483,9000000000000
   Treasury Stock0000000000000
   Other Stockholders Equity 
4,191,259
4,700,869
6,934,964
9,059,873
11,611,232
19,506,601
23,188,500
24,279,800
17,456,300
-31,126,500
8,128,200
7,629,700
7,291,800
7,291,8007,629,7008,128,200-31,126,50017,456,30024,279,80023,188,50019,506,60111,611,2329,059,8736,934,9644,700,8694,191,259



Balance Sheet

Currency in INR. All numbers in thousands.




Cash Flow

Currency in INR. All numbers in thousands.




Income Statement

Currency in INR. All numbers in thousands.


Latest Income Statement (annual, 2023-03-31)

Gross Profit (+$)
totalRevenue56,526,200
Cost of Revenue-17,088,200
Gross Profit39,438,00039,438,000
 
Operating Income (+$)
Gross Profit39,438,000
Operating Expense-35,108,900
Operating Income4,377,8004,329,100
 
Operating Expense (+$)
Research Development290,700
Selling General Administrative2,410,500
Selling And Marketing Expenses9,523,000
Operating Expense35,108,90012,224,200
 
Net Interest Income (+$)
Interest Income501,700
Interest Expense-501,700
Other Finance Cost-501,700
Net Interest Income-501,700
 
Pretax Income (+$)
Operating Income4,377,800
Net Interest Income-501,700
Other Non-Operating Income Expenses0
Income Before Tax (EBT)3,545,9005,209,600
EBIT - interestExpense = 3,545,900
3,546,000
3,921,600
Interest Expense501,700
Earnings Before Interest and Taxes (EBIT)4,047,6004,047,600
Earnings Before Interest and Taxes (EBITDA)6,801,900
 
After tax Income (+$)
Income Before Tax3,545,900
Tax Provision-126,100
Net Income From Continuing Ops3,419,8003,419,800
Net Income3,419,900
Net Income Applicable To Common Shares3,419,900
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses52,197,100
Total Other Income/Expenses Net-831,800501,700
 

Technical Analysis of Alembic Pharmaceuticals Limited
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Alembic Pharmaceuticals Limited. The general trend of Alembic Pharmaceuticals Limited is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Alembic Pharmaceuticals Limited's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Alembic Pharmaceuticals Limited.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1,049 < 1,094.

The bearish price targets are: 901.80 > 892.00 > 839.00.

Tweet this
Alembic Pharmaceuticals Limited Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Alembic Pharmaceuticals Limited. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Alembic Pharmaceuticals Limited Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Alembic Pharmaceuticals Limited.

Alembic Pharmaceuticals Limited Daily Moving Average Convergence/Divergence (MACD) ChartAlembic Pharmaceuticals Limited Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Alembic Pharmaceuticals Limited. The current adx is .

Alembic Pharmaceuticals Limited Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Alembic Pharmaceuticals Limited.

Alembic Pharmaceuticals Limited Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Alembic Pharmaceuticals Limited.

Alembic Pharmaceuticals Limited Daily Relative Strength Index (RSI) ChartAlembic Pharmaceuticals Limited Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Alembic Pharmaceuticals Limited.

Alembic Pharmaceuticals Limited Daily Stochastic Oscillator ChartAlembic Pharmaceuticals Limited Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Alembic Pharmaceuticals Limited.

Alembic Pharmaceuticals Limited Daily Commodity Channel Index (CCI) ChartAlembic Pharmaceuticals Limited Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Alembic Pharmaceuticals Limited.

Alembic Pharmaceuticals Limited Daily Chande Momentum Oscillator (CMO) ChartAlembic Pharmaceuticals Limited Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Alembic Pharmaceuticals Limited.

Alembic Pharmaceuticals Limited Daily Williams %R ChartAlembic Pharmaceuticals Limited Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Alembic Pharmaceuticals Limited.

Alembic Pharmaceuticals Limited Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Alembic Pharmaceuticals Limited.

Alembic Pharmaceuticals Limited Daily Average True Range (ATR) ChartAlembic Pharmaceuticals Limited Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Alembic Pharmaceuticals Limited.

Alembic Pharmaceuticals Limited Daily On-Balance Volume (OBV) ChartAlembic Pharmaceuticals Limited Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Alembic Pharmaceuticals Limited.

Alembic Pharmaceuticals Limited Daily Money Flow Index (MFI) ChartAlembic Pharmaceuticals Limited Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Alembic Pharmaceuticals Limited.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-23WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-29WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-18CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-04MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-05WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-12ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-15STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-20MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-25RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-23RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-14MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-08MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Alembic Pharmaceuticals Limited Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Alembic Pharmaceuticals Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose960.000
Total1/1 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Alembic Pharmaceuticals Limited with someone you think should read this too:
  • Are you bullish or bearish on Alembic Pharmaceuticals Limited? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Alembic Pharmaceuticals Limited? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Alembic Pharmaceuticals Limited

I send you an email if I find something interesting about Alembic Pharmaceuticals Limited.


Comments

How you think about this?

Leave a comment

Stay informed about Alembic Pharmaceuticals Limited.

Receive notifications about Alembic Pharmaceuticals Limited in your mailbox!